Phaeosynt Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$150K
- Investors
-
15
Phaeosynt General Information
Description
Manufacturer of animal-free antibodies intended for the research and diagnostic industries. The company's technology utilizes microalgae to produce reproducible batches of antibodies and fusion proteins, enabling diagnostic manufacturers and consumer brands to access serum-free biological components and white-label rapid test solutions.
Contact Information
Website
www.phaeosynt.comCorporate Office
- Walderseestr. 7Feodor-Lynen-Street 31
- 30625 Hanover
- Germany
Corporate Office
- Walderseestr. 7Feodor-Lynen-Street 31
- 30625 Hanover
- Germany
Phaeosynt Timeline
Phaeosynt Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Accelerator/Incubator | 14-Sep-2026 | $150K | Completed | Generating Revenue | ||
| 7. Accelerator/Incubator | 01-Jan-2026 | Completed | Generating Revenue | |||
| 6. Seed Round | 12-Feb-2025 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 16-Dec-2024 | Completed | Generating Revenue | |||
| 4. Seed Round | 01-Dec-2023 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 2. Accelerator/Incubator | 01-Jan-2023 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 18-Jul-2022 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Phaeosynt Patents
Phaeosynt Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250314652-A1 | Immunoassay for detecting biologically active proteins | Pending | 15-Sep-2022 | ||
| EP-4587833-A1 | Immunoassay for verifying biologically active proteins | Active | 15-Sep-2022 | ||
| EP-4587833-B1 | Immunoassay for verifying biologically active proteins | Active | 15-Sep-2022 | ||
| EP-4587833-C0 | Immunoassay for verifying biologically active proteins | Active | 15-Sep-2022 | ||
| WO-2024056905-A1 | Immunoassay for verifying biologically active proteins | Inactive | 15-Sep-2022 | G01N33/54388 |
Phaeosynt Signals
Phaeosynt Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Morgan Stanley Inclusive & Sustainable Ventures | Accelerator/Incubator | Minority | ||
| Nordic Mentor Network For Entrepreneurship | Accelerator/Incubator | |||
| Fonde Ventures | Accelerator/Incubator | Minority | ||
| NBank Capital | Venture Capital | Minority | ||
| PSD Braunschweig Verwaltungs | Corporate Venture Capital | Minority |
Phaeosynt FAQs
-
When was Phaeosynt founded?
Phaeosynt was founded in 2021.
-
Where is Phaeosynt headquartered?
Phaeosynt is headquartered in Hanover, Germany.
-
What is the size of Phaeosynt?
Phaeosynt has 10 total employees.
-
What industry is Phaeosynt in?
Phaeosynt’s primary industry is Biotechnology.
-
Is Phaeosynt a private or public company?
Phaeosynt is a Private company.
-
What is Phaeosynt’s current revenue?
The current revenue for Phaeosynt is .
-
How much funding has Phaeosynt raised over time?
Phaeosynt has raised $1.91M.
-
Who are Phaeosynt’s investors?
Morgan Stanley Inclusive & Sustainable Ventures, Nordic Mentor Network For Entrepreneurship, Fonde Ventures, NBank Capital, and PSD Braunschweig Verwaltungs are 5 of 15 investors who have invested in Phaeosynt.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process